RARE News and Press, Ultragenyx Pharmaceutical Inc. From 12/08/23

2023-12-08 17:07:24 ET More on Ultragenyx Pharmaceutical Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade) Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. 2023 Q3 - Res...

6 th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company fo...

2023-11-14 21:51:36 ET Summary Ultragenyx shows clinical innovation in rare diseases; financial growth is offset by high net loss and cash burn. Recent earnings indicate YOY revenue growth but a substantial net loss; operating expenses have decreased. Ultragenyx's liquid asset...

NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the c...

2023-11-02 22:29:10 ET Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Conference Call November 02, 2023 05:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris ...

2023-11-02 17:01:04 ET More on Ultragenyx Pharmaceutical Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade) Ultragenyx Pharmaceutical prices $300 million securities offering Seeking Alpha’s Quant Rating on Ultra...

Third quarter 2023 total revenue of $98.1 million, Crysvita ® revenue of $74.9 million and Dojolvi ® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojol...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

Ultragenyx Pharmaceutical Inc. (RARE) is expected to report $-2.08 for Q3 2023

2023-11-01 13:17:04 ET More on Ultragenyx Pharmaceutical Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade) Ultragenyx Pharmaceutical prices $300 million securities offering Seeking Alpha’s Quant Rating on Ultra...